| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 80.90 | 0.8% | 25.2% |
| Total Income | 86.63 | 0.6% | 26.2% |
| Expenditure | 75.45 | 1.6% | 38.9% |
| PBT | 11.17 | 5.5% | 21.8% |
| Net Profit | 8.28 | 10.3% | 22.0% |
| OPM | 16.35% | 0.11pp | 10.75pp |
| NPM | 9.55% | 1.17pp | 5.91pp |
| EPS | 0.72 | 10.0% | 31.4% |
25% revenue growth masks 22% PAT decline; margin recovery contingent on investments
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
FY27 ₹350 Cr target reaffirmed; Q1-Q2 tracking at ₹161.2 Cr is on pace. EBITDA margin guidance maintained at 22-25% but delivery in Q2 at 16.35% indicates near-term miss.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue growth (+25.2% YoY) and pipeline expansion (₹1,200 Cr) support long-term narrative, but Q2 margin collapse (16.35% EBITDA vs 24-25% guided) and PAT decline of 22% signal execution risk. Guidance maintained but contingent on unproven investment returns; margin recovery timing vague.
₹80.9 Cr
Revenue · +25.2% YoY₹8.3 Cr
Reported PAT · −22% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue growth of 25.2% YoY shows business continues to grow
METQ2 revenue ₹80.9 Cr vs ₹64.61 Cr in Q2 FY26, exactly 25.2% growth
No structural change in margin profile
MISSEBITDA margin fell from 29.3% to 16.35% (13pp drop); PAT margin fell from 10.6 Cr to 8.3 Cr (-22%)
H1 growth at 33.9% demonstrates momentum
METH1 revenue ₹161.2 Cr vs ₹120.3 Cr, exactly 33.9% YoY
Pipeline improved by 20% in recent quarters
OVERSTATEDPipeline ₹1,200 Cr now vs ₹900 Cr at FY26-27 start = 33% growth (higher than stated 20%)
EBITDA margin to reach 22-25% once investments yield
METCurrent Q2 margin 16.35%, requires 6-9pp improvement; timing not specified beyond 'next couple of quarters'
Earnings quality
What changed since the last call
Pipeline growth acceleration
UpgradePipeline grew ₹300 Cr (₹900 Cr → ₹1,200 Cr, 33% growth) in first half FY27; sales team geographic expansion contributing
Margin pressure acknowledgement
DowngradeEBITDA margin fell 13pp YoY to 16.35% from 29.3%; management now explicitly expects recovery to only 22-25%, not back to 30-31% prior levels
AI revenue timeline
New16 AI prototypes in development; management expects meaningful AI revenue in 'coming quarter' (Q3+); prior call did not quantify AI revenue expectations
AQA deployment status
NeutralAQA remains on track with phased rollout; customer-side delays in acceptance testing; no revenue recognition yet despite earlier guidance of ₹12-15 Cr FY27 contribution
The Q&A
Analysts pressed hard on margin compression (Mahesh Kumar, MU Investments) and customer concentration risk. Management acknowledged concentration risk openly but defended it via contracting model; on margins, deflected to investments being temporary. Q&A tone: management held ground but analyst skepticism on margin recovery timeline and investment ROI was evident.
Margin pressure — Mahesh Kumar, MU Investments
AnsweredDecline is due to investments in sales team and training (charged to P&L), not operational. No pressure on margins from one-time items; expect EBITDA margin 22-25% once investments yield.
Customer concentration — Mahesh Kumar, MU Investments
AnsweredOne large customer has multiple business divisions with separate P&L owners; risk of losing all is remote. Have 5-year plan to reduce concentration to <25-30% through new customer wins and diversification.
AI monetization — Mahesh Kumar, MU Investments
Partial16 AI prototypes developed; expect AI-specific revenues in coming quarter; currently customer-centric AI but scaling to product-based offerings.
Order pipeline — Juzar Daruwala, Aavya Asset
AnsweredPipeline ₹900 Cr at start FY26-27, now ₹1,200 Cr. Very healthy. Confident of converting this into delivery and making ₹350 Cr target on year-on-year basis.
AQA program status — Abhishek Kamdar, Value Plus Advisors
PartialMoved forward on e-marking (98.6% automation accuracy); now on extraction (handwriting to machine-readable text). Workshops with UK examination teams showing significant progress.
Investment ROI timing — Jinisha, SK Investments
Partial20-25% of growth should come from these investments. Sales team conversion takes 3-4 months engagement to deployment; it's a long journey, can't just add sales team and expect immediate results.
VTCT platform — Divya Reddy, Sunshine Investments
AnsweredVTCT: 500 tests/month Sept, ~25,000 tests Oct, expecting 30,000/month. Saras: pilot devices with customers (Africa, UK), currently POC; integration in testing phase.
Education tech sustainability — Divya Reddy, Sunshine Investments
PartialEducation tech is key growth driver (60.75% of Q2 revenue). ETS is large customer with 12 business divisions; multiple growth avenues with them and other education customers including university partnerships.
Guidance
FY27 total revenue ₹350-360 Cr (78% YoY from ₹197 Cr base)
HighManagement reaffirmed confidence; H1 ₹161.2 Cr implies H2 needs ₹189-199 Cr. H1 growth 33.9% suggests achievable if sustained.
EBITDA margin to reach 22-25% once investments yield
MediumCurrent Q2 at 16.35%; management expects recovery in 'next couple of quarters' as ₹20.3 Cr investments pay off. Prior guidance 24-25%, now slightly lower.
Strategic investments ₹20.3 Cr in FY27 for sales expansion, leadership, talent, product development
HighAlready partially deployed (visible in Q1-Q2 margins); ongoing through FY27 end; no additional capex beyond this guided
Risks the call surfaced
Customer concentration
High~75% revenue from top 5 customers (ETS and British Council mentioned). Single loss could materially impact revenue. Large customer is actually 12 business divisions but decision-making slow and challenging.
Margin compression
HighEBITDA margin fell 13pp YoY (29.3% → 16.35%); PAT down 22% despite 25% revenue growth. Management attributes to investments, but if these don't yield, margin recovery to 22-25% may be optimistic.
AQA revenue delays
MediumAQA (assessment platform) guided to contribute ₹12-15 Cr in FY27, but customer-side UAT delays are causing revenue deferral. Program experiencing delays in acceptance testing and user adoption.
Geographic expansion ROI
Medium₹20.3 Cr invested in sales teams and presence in US, UK, Middle East, Canada. ROI timeline vague; management cites 3-4 months to engagement, then 3-6 months to deployment. May not materialize in FY27.
AI revenue uncertainty
Medium16 AI prototypes developed but no named commercial deployments. Management expects 'meaningful AI revenue contribution' in coming quarter but no quantification. Risk of over-promising, under-delivering.
Management
Score 6/10. Candid on challenges (customer concentration, margin pressure, AQA delays); defensive on execution; vague on timelines for investment ROI and AI monetization. Revenue track record good (25.2% YoY, H1 33.9% growth); margin track record weak (EBITDA down 13pp despite guidance to maintain 24-25%); AQA launch delayed vs original expectations.
1 · Q3 FY27
AI-specific revenue ramp; 16 prototypes to commercial deployments
2 · Q3-Q4 FY27
AQA e-marking platform acceptance; UK examination teams workshops underway
3 · Next 2-3 quarters
Geographic expansion benefits (US, UK, Middle East, Canada) from sales teams now deployed
Guidance maintained but contingent on unproven investment returns; margin recovery timing vague.
25% Revenue Growth Masks a 22% Profit Collapse; Margin Recovery Still Unproven
Excelsoft delivered strong topline momentum (+25.2% YoY) and a ₹1,200 Cr pipeline, but profitability fell off a cliff — PAT down 22% despite guidance for margin recovery. The question is whether ₹20.3 Cr in strategic investments will actually yield the promised 22–25% EBITDA margin, or whether the business model itself has shifted.
₹80.9 Cr
+25.2% YoY; H1 ₹161.2 Cr, +33.9%
₹8.3 Cr
-22% YoY; H1 ₹16.1 Cr, +6.2%
16.35%
vs 29.3% prior year; guided 22–25%
₹20.3 Cr
Sales teams, talent, product dev; charged to P&L
The quarter embodies a contradiction: Excelsoft is growing the top line hard (+25.2% YoY, H1 tracking to ₹350 Cr full-year target) yet profitability is evaporating. On a reported basis, PAT fell ₹2.5 Cr (-22% YoY) even as revenue grew ₹16.3 Cr. The company attributes the margin collapse entirely to ₹20.3 Cr in strategic investments — sales team deployment across US, UK, Middle East, Canada; talent hiring; AI product development. The claim is mechanical: spend first, revenue later. The risk is that this may be permanent, not temporary.
What management claimed vs. what holds up
Revenue growth of 25.2% YoY shows business continues to grow
H1 growth at 33.9% demonstrates momentum
No structural change in margin profile — decline is investment-driven, not operational
Pipeline improved by 20% in recent quarters
EBITDA margin to recover to 22–25% once investments yield
Top-line claims hold up completely. Q2 revenue ₹80.9 Cr vs ₹64.61 Cr prior year = exactly 25.2% growth. H1 ₹161.2 Cr vs ₹120.3 Cr = exactly 33.9%. The pipeline claim is slightly overstated: management said 20% growth, but actual is ₹1,200 Cr now vs ₹900 Cr at FY26-27 start = 33% growth — higher than stated, a rare management miss in the conservative direction. The margin claim is contradicted by the numbers. Management asserts 'no structural change' and frames the decline as temporary. Yet EBITDA margin fell 13 percentage points (29.3% → 16.35%) — the largest move in either direction would erase this. Management's own prior guidance was 24–25% for FY27; Q2 came in at 16.35%, a 8–9 pp miss. The company now guides 22–25% recovery 'in the next couple of quarters,' but with no evidence of traction yet and ₹20.3 Cr still flowing out, credibility on the 22–25% target is medium at best.
What changed on this call
Pipeline acceleration (positive): ₹300 Cr added to the pipeline in H1 FY27 (₹900 Cr → ₹1,200 Cr). This is a 33% jump and management credibly links it to geographic expansion teams now deployed. This is real and was not emphasized on the prior call. Margin guidance effectively revised downward (negative): Prior guidance on the call was EBITDA margin 24–25% with a prior-year baseline of 30–31%. Q2 delivered 16.35%, and management now calibrates recovery to 22–25%, not the prior 30–31%. This is a silent downgrade: even in recovery, Excelsoft expects permanently lower margins than two quarters ago. AQA revenue timing now uncertain (negative): This assessment platform was guided to contribute ₹12–15 Cr in FY27; customer-side UAT delays and acceptance testing backlog are causing deferral. Program moved to e-marking (98.6% automation) and is working on extraction (handwriting to machine text), but revenue recognition now deferred — exact timing unclear. AI revenue timeline extended (neutral/negative): 16 AI prototypes developed. Management expects 'meaningful AI revenue contribution' in the 'coming quarter' (Q3+) but offers no quantification. This is aspirational without a number. Geographic expansion costs now visible (negative): ₹20.3 Cr investment is now on the P&L (charged to operating expenses), not capitalized. This depresses reported margins and will persist through FY27 end. Prior call did not explicitly quantify this investment or its timing.
Revenue momentum accelerating: H1 +33.9% YoY, tracking ₹350 Cr FY27 target
PAT is -22% YoY despite 25% revenue growth — profitability disconnected from growth
Pipeline ₹1,200 Cr (33% growth) provides visibility into future order intake
75% revenue from top 5 customers; single loss materially impacts revenue; procurement cycle in large orgs is slow
Education tech segment (60.75% of revenue) growing 41.9% YoY; structural tailwind
ETS (a single customer with 12 divisions) is bulk of education tech; concentration risk poorly managed
Strong cash position (₹407 Cr, no debt) funds ₹20.3 Cr investments without external funding
Cash spent today on investments; ROI timing uncertain (3–6 months stated, vague on volume impact)
Margin recovery to 22–25% is mechanism-driven (investments + pipeline) and reaffirmed by management
Q2 EBITDA margin 16.35% vs 24–25% guided = 8–9 pp miss; recovery credibility weakened; no evidence yet
Operating cash flow ₹34.7 Cr (H1) strong; business generates cash despite P&L pressure
AQA revenue deferred due to customer UAT delays; execution risk in large-org sales cycles
Risks, ranked by how much they should concern a holder
Margin recovery delayed or undelivered
HighQ2 EBITDA margin 16.35% is 8–9 pp below guided 24–25%. If ₹20.3 Cr investments don't yield and margins stay at 16–18%, PAT will remain depressed for quarters. Profitability would be locked in at 40% below prior baselines.
Customer concentration (75% top 5, ETS-heavy)
HighSingle large customer loss would crater revenue. ETS has 12 divisions but purchasing decisions are slow and centralized. Concentration to <30% is a 5-year goal; no interim milestones. Macro slowdown in gov procurement (ETS is tied to standardized testing demand) would hit Excelsoft hard.
AQA revenue deferral extends further
MediumGuided ₹12–15 Cr FY27 contribution; customer UAT delays are already pushing timing. Further delays compress H2 options and lower full-year guidance. Would compound margin miss.
Geographic expansion ROI doesn't materialize
Medium₹20.3 Cr invested across 4 new geographies (US, UK, Middle East, Canada). Sales team conversion takes 3–6 months; deployment to revenue is 9+ months total. If new geographies don't close deals, capex is wasted and margins stay compressed.
AI revenue ramp slower than promised
Medium16 prototypes but no named commercial deployments. Management expects 'meaningful revenue' in Q3+ but doesn't quantify. Risk of over-promise and under-deliver (common in AI narratives); if AI doesn't materialize, TAM for new products shrinks.
How the street is reading this
Price action and valuation context: Excelsoft trades at ₹76.36 as of Nov 11, down 46.45% from its all-time high of ₹142.59. The stock is trading below its 20-day SMA (₹78.63), 50-day SMA (₹78.45), and 200-day SMA (₹80.28) — a bearish setup. RSI is neutral at 45.9, not oversold. The stock has rebounded 15% off its 52-week low of ₹66.4, but remains in the lower half of its 52-week range. This is not a panic sell-off; it's a measured, multi-month drift lower reflecting genuine concerns about profitability. Institutional positioning: FII and DII are both reducing exposure. FII holdings dropped 0.25 pp QoQ (1.37% → 1.12%), and DII dropped 0.95 pp (4.05% → 3.10%). Promoter ownership stable at 59.09%. The reduction is quiet but steady — not a flight, but a retreat. This aligns with the fundamental concern: growth without profits is not a long-term holding for institutions. Insider and bulk activity: Bulk deals over the past 6 months show NK Securities Research trading blocks in and out (Sep 09 at ₹76.41 buy/sell, May 22 at ₹97.07 buy/sell). These are likely index rebalancing or derivative hedging, not significant insider positioning. No red flags. The market's own verdict: The price action confirms the fundamental story: growth is real, but profitability risk is material. The 46% drawdown from ATH is steep, but the absence of a panic sell (RSI not deeply oversold, volume normal) suggests the market is waiting for evidence of margin recovery. If Q3 delivers on the 22–25% EBITDA margin target, the stock should recover. If margins stay at 16–18%, further downside is likely.
The debate
1 · Q3 EBITDA margin (the threshold)
Does it move toward 22–25% or stay at 16–18%? This single number resolves whether the investment thesis holds. If margin stays low, confidence in recovery evaporates and downside risk accelerates.
2 · AQA revenue recognition (acceptance testing clearance)
When does UAT clear and revenue start flowing? ₹12–15 Cr guided for FY27 is at risk if delays extend past Q4. This is a binary: acceptance clears, or it doesn't.
3 · New customer wins and concentration reduction
Do geographic expansion sales teams close deals with non-ETS customers? Pipeline grew ₹300 Cr, but *which* customers? If new revenue still comes from ETS divisions or British Council, concentration risk persists. Evidence of new customer logos in Q3 earnings would matter.
Excelsoft is not in distress — cash flow is healthy, revenue is growing, and the long-term narrative (education tech, geographic expansion, AI) is intact. But the gap between the reported quarter and the guided margin is too large to overlook. The company must prove it can invest and grow *and* manage margins, not one or the other. The next two quarters will determine whether this is a temporary margin trough or a permanent shift in the business model. Until margin recovery is visible, the hold rating stands.
The number to track: Q3 EBITDA margin. If it's >20%, the stock should recover. If it stays <18%, the 46% drawdown from ATH will look like early innings, not a buying opportunity.